Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2024-10-11 DOI:10.1002/alz.14317

Val J. Lowe, Carly T. Mester, Emily S. Lundt, Jeyeon Lee, Sujala Ghatamaneni, Alicia Algeciras-Schimnich, Michelle R. Campbell, Jonathan Graff-Radford, Aivi Nguyen, Hoon-Ki Min, Matthew L. Senjem, Mary M. Machulda, Christopher G. Schwarz, Dennis W. Dickson, Melissa E. Murray, Karunya K. Kandimalla, Kejal Kantarci, Bradley Boeve, Prashanthi Vemuri, David T. Jones, David Knopman, Clifford R. Jack Jr., Ronald C. Petersen, Michelle M. Mielke

{"title":"Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers","authors":"Val J. Lowe, Carly T. Mester, Emily S. Lundt, Jeyeon Lee, Sujala Ghatamaneni, Alicia Algeciras-Schimnich, Michelle R. Campbell, Jonathan Graff-Radford, Aivi Nguyen, Hoon-Ki Min, Matthew L. Senjem, Mary M. Machulda, Christopher G. Schwarz, Dennis W. Dickson, Melissa E. Murray, Karunya K. Kandimalla, Kejal Kantarci, Bradley Boeve, Prashanthi Vemuri, David T. Jones, David Knopman, Clifford R. Jack Jr., Ronald C. Petersen, Michelle M. Mielke","doi":"10.1002/alz.14317","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Understanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population-based or neuropathologic comparisons have been reported.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Participants 50+ years with Aβ PET and Aβ CSF biomarkers (phosphorylated tau [p-tau]181/Aβ42, <i>n</i> = 505, and Aβ42/40, <i>n</i> = 54) were included from the Mayo Clinic Study on Aging. From these participants, an autopsy subgroup was identified (<i>n</i> = 47). The relationships of Aβ PET and Aβ CSF biomarkers were assessed cross-sectionally in all participants and longitudinally in autopsy data.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Cross-sectionally, more participants were Aβ PET+ versus Aβ CSF− than Aβ PET− versus Aβ CSF+ with an incremental effect when using Aβ PET regions selected for early Aβ deposition. The sensitivity for the first detection of Thal phase ≥ 1 in longitudinal data was higher for Aβ PET (89%) than p-tau181/Aβ42 (64%).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Aβ PET can detect earlier cortical Aβ deposition than Aβ CSF biomarkers. Aβ PET+ versus Aβ CSF− findings are several-fold greater using regional Aβ PET analyses and in peri-threshold-standardized uptake value ratio participants.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Amyloid beta (Aβ) positron emission tomography (PET) has greater sensitivity for Aβ deposition than Aβ cerebrospinal fluid (CSF) in early Aβ development.</li>\n \n <li>A population-based sample of participants (<i>n</i> = 505) with PET and CSF tests was used.</li>\n \n <li>Cortical regions showing early Aβ on Aβ PET were also used in these analyses.</li>\n \n <li>Neuropathology was used to validate detection of Aβ by Aβ PET and Aβ CSF biomarkers.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"20 11","pages":"8097-8112"},"PeriodicalIF":13.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14317","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14317","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Understanding the relationship between amyloid beta (Aβ) positron emission tomography (PET) and Aβ cerebrospinal fluid (CSF) biomarkers will define their potential utility in Aβ treatment. Few population-based or neuropathologic comparisons have been reported.

METHODS

Participants 50+ years with Aβ PET and Aβ CSF biomarkers (phosphorylated tau [p-tau]181/Aβ42, n = 505, and Aβ42/40, n = 54) were included from the Mayo Clinic Study on Aging. From these participants, an autopsy subgroup was identified (n = 47). The relationships of Aβ PET and Aβ CSF biomarkers were assessed cross-sectionally in all participants and longitudinally in autopsy data.

RESULTS

Cross-sectionally, more participants were Aβ PET+ versus Aβ CSF− than Aβ PET− versus Aβ CSF+ with an incremental effect when using Aβ PET regions selected for early Aβ deposition. The sensitivity for the first detection of Thal phase ≥ 1 in longitudinal data was higher for Aβ PET (89%) than p-tau181/Aβ42 (64%).

DISCUSSION

Aβ PET can detect earlier cortical Aβ deposition than Aβ CSF biomarkers. Aβ PET+ versus Aβ CSF− findings are several-fold greater using regional Aβ PET analyses and in peri-threshold-standardized uptake value ratio participants.

Highlights

Amyloid beta (Aβ) positron emission tomography (PET) has greater sensitivity for Aβ deposition than Aβ cerebrospinal fluid (CSF) in early Aβ development.
A population-based sample of participants (n = 505) with PET and CSF tests was used.
Cortical regions showing early Aβ on Aβ PET were also used in these analyses.
Neuropathology was used to validate detection of Aβ by Aβ PET and Aβ CSF biomarkers.

Abstract Image

查看原文本刊更多论文

与脑脊液生物标记物相比，淀粉样蛋白 PET 能更早地检测出脑 Aβ 的沉积。

导言：了解淀粉样β（Aβ）正电子发射断层扫描（PET）和Aβ脑脊液（CSF）生物标志物之间的关系将确定它们在Aβ治疗中的潜在作用。很少有基于人群或神经病理学的比较报告：方法：从梅奥诊所老龄化研究（Mayo Clinic Study on Aging）中选取 50 岁以上、具有 Aβ PET 和 Aβ 脑脊液生物标志物（磷酸化 tau [p-tau]181/Aβ42, n = 505 和 Aβ42/40, n = 54）的参与者。从这些参与者中确定了一个尸检亚组（n = 47）。对所有参与者的 Aβ PET 和 Aβ CSF 生物标志物的关系进行了横向评估，并对尸检数据进行了纵向评估：结果：横断面上，Aβ PET+与Aβ CSF-相比，Aβ PET-与Aβ CSF-相比，Aβ PET-与Aβ CSF+的参与者人数更多，当使用Aβ PET选择早期Aβ沉积区域时，效果会递增。在纵向数据中，Aβ PET首次检测Thal期≥1的灵敏度（89%）高于p-tau181/Aβ42（64%）：讨论：与Aβ CSF生物标记物相比，Aβ PET能更早地检测到皮质Aβ沉积。使用区域 Aβ PET 分析和在阈值周围标准化摄取值比值的参与者中，Aβ PET+ 与 Aβ CSF- 的结果相差数倍：淀粉样β（Aβ）正电子发射断层扫描（PET）对早期Aβ沉积的敏感性高于Aβ脑脊液（CSF）。该研究使用了基于人群的样本（n = 505），对 PET 和 CSF 进行了检测。在这些分析中还使用了在 Aβ PET 上显示早期 Aβ 的皮层区域。神经病理学用于验证 Aβ PET 和 Aβ CSF 生物标记物对 Aβ 的检测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.